OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2023-03-31-accounts

Sickle Cell & Thalassaemia Support Project

Annual Report

2023-2024

sctsp.org.uk

Company No: 3575079 Charity No: 1077687

Chairman’s Remarks

Another year gone, and another opportunity to say thank you to everyone for their support and contributions over the past year. A big thanks also to our sponsors, whose support has meant we were able to reach out more to those individuals and families in need . Everyone's efforts - however small, is much appreciated - and makes a difference. We are trying to respond more to those we aim to serve and hope, moving forward, that service users can benefit even more from the services we provide. Finally, my particular thanks to the staff and Board Members for their efforts and enduring commitment to the organisation.

Our Impact

The organisation was established in 1990 to support individuals and families affected by Sickle Cell and Thalassaemiawe have maintained our business and have been working alongside healthcare professionals, parents and people living with the conditions to raise awareness of the disorders. Our main aim is to support those living with Sickle Cell and Thalassaemia, empowering them to build resilience to achieve their full potential.

From April 2023-March 2024, we received and processed 723 unusual blood results.

To learn more about this process, please visit https://www.nhs.uk/pregnancy and search for screening for sickle. We have supported service users with their health plans and we have worked with schools to provide a new or reviewed care plan for 160 children. We have also supported many affected adults, children and their families with their wellbeing through multiple activities and events.

Number of Sickle Cell & Thalassaemia Clients: Areas of support: 152 Adults, 179 Children Wolverhampton, Walsall, Dudley and the surrounding areas.

Services available:

The project collaborates with the NHS to support sickle cell and thalassaemia screening. Counselling ensures individuals receive accessible information about haemoglobinopathies, focusing on genetic, health and psychological support while respecting cultural backgrounds.

Key Services include:

The project also provides training for healthcare professionals, raises awareness in schools, and promotes community education to enhance understanding and management of these conditions.

Finances

----- Start of picture text -----
Income Expenditure
NHS Contracts (62.8%) Salary & On Cost (78.7%)
Donations & Other (30.8%) Other (12%)
Investments (6.4%) Social support (5.4%)
Premises (3.9%)
----- End of picture text -----

National Grid

Helping families stay warm during winter

The Sickle Cell & Thalassaemia Support Project received funding from the National Grid (nationalgrid.co.uk) to support our service users to stay warm throughout winter. This project ran from January to March 2024 and supported many families affected by Sickle Cell and Thalassaemia blood disorders.

The project aimed to provide vital resources and support to individuals and families affected by sickle cell and thalassaemia blood disorders to keep their homes warm and energy bills low. On Tuesday 6th February, we held an event at Bob Jones Community Hub with organisations such as Act-on Energy, LEAP, Severn Trent and Wolverhampton City Council providing free support and advice.

As part of this project, we were able to distribute nearly 100 warm packs which included items such as electric blankets, heaters, draft excluders, duvets, and radiator reflectors. These resources provided much needed warm and comfort to those affected by the conditions.

National Lottery Community Fund

Empowering Parents and Young People

The Sickle Cell & Thalassaemia Support Project received funding from the National Lottery Community Fund (tnlcommunityfund.org.uk) to empower parents and young people impacted by Sickle Cell and Thalassaemia blood disorders.

We provided a variety of workshops for parents around building self-confidence, developing a positive mindset and managing anxiety and worries. Living with a serious blood disorder can be challenging for both the affected individual and their families. Supporting parents with their wellbeing meant they were in a better position to support their children.

We were also able to provide activities to support young peoples wellbeing such as a tour and storytelling session at Wolverhampton Grand Theatre and a Sports Day.

Collins Aerospace

Supporting the project through activities and fundraising

Activities

We are immensely grateful for all the support we received this year from Collins Aerospace in Wolverhampton. Over the year, the Sickle Cell & Thalassaemia Support Project team and the families they support have been able to get involved in a variety of events and activities.

Collins Aerospace Family Fun Day was a great event with plenty of free activities to get involved with. The Sickle Cell & Thalassaemia Support Project team along with a handful of families they support were able to enjoy face painting, bouncy castles, free ice cream and much more.

Collins Aerospace have involved the young people supported by our project in STEM activities including a STEM day on their site and a STEM careers talk at Graiseley Family Hub in Wolverhampton. These events provides a unique opportunity to explore the world of science and engineering and careers available.

During Black History Month, we had the privilege of joining an inspiring gathering featuring Former Heavyweight World Champion Frank Bruno MBE. Frank Bruno spoke about his mental health journey and how he manages it on a day-today basis. We were also able to talk at this event, raising awareness of Sickle Cell and Thalassaemia blood disorders.

Just before Easter, Collins Aerospace donated 100 Easter Eggs for the families we support. We ran an Easter Art Event allowing young people to get involved with a variety of creative and fun activities. Every child who attended enjoyed leaving with an Easter Egg to enjoy over Easter.

Fundraising

We were grateful for all the support received by Collins Aerospace fundraising for the Sickle Cell & Thalassaemia Support Project.

Collins Aerospace were the main sponsor for Wolverhampton Krazy Races in August 2023, raising money for the project as part of this event.

Collins Aerospace also greatly supported our Christmas Donations Event. This included providing us with the funds by buy food and toiletries to help support families affected by Sickle Cell and Thalassaemia stay well over Christmas. They also donated a variety of clothes for adults and children which we were able to hand out at our event.

.

The New Black Film Collective

Media project for young people affected by Sickle Cell Disease

With funding from the BBC Children in Need’s We Move Fund: Youth Social Action, The New Black Film Collective launched their Sickle Cell Warriors project to give young people affected by sickle cell the chance to make an impact through a media project.

In partnership with The New Black Film Collective, we accompanied young people supported by the Sickle Cell & Thalassaemia Support Project at a series of events including a research trip in London and speaking on WCR FM, a local radio station in Wolverhampton.

Cash For Kids

Bringing smiles to young people

Cash for Kids is a grant-giving charity helping the children that need it most across the UK. Their mission is to improve the lives of disadvantaged children and young people in our communities who are affected by poverty, illness, neglect or have additional needs.

On Tuesday 29th August 2023, a handful of the young people we support and some of their parents had an unforgettable visit to Wolverhampton Grand Theatre. A tour took place for older children and a story telling session for younger ones. Thanks to Cash for Kids, we were able to give 50 young people a gift voucher, allowing them to do something or buy something they wouldn’t have usually had the opportunity to do. Some young people chose to spend their vouchers on clothes and back-to-school stationary of their choice, others chose to enjoy a meal at a restaurant with their family.

Cat’s Great North Run

Raising money for our hardship fund

On Sunday 10th September 2023, Cat participated in the Great North Run. She took it upon herself to run in the Great North Run with the goal of raising £500 for our 'Hardship Fund'. This Fund plays a crucial role in providing direct support for families when they find themselves at their most vulnerable.

We understand that times have been tough for everyone, but we are truly touched by the outpouring of support from our community. Thanks to your contributions, Cat not only completed the Great North Run in an impressive 2 hours and 11 minutes but also raised an astounding total of £1670 for the Sickle Cell & Thalassaemia Support Project.

Testimonials

The staff at the project are amazing very friendly, welcoming and supportive. I would like to say you are doing a would job and thanks for supporting my family and I throughout the years.- Wolverhampton Adult

(National Grid Project) Yes, it was really helpful. Most especially this time that things are expensive. It was a great relief support.- Walsall Parent

I really thank you for all that you do. It was extremely appreciated- Walsall Adult

(Cash for Kids) I am now more confident I will be able to purchase appropriate clothing for the colder weather. It will really help with the cost. My finances are very stretched at the moment.- Dudley Parent

Our Supporterss

COMPANY REGISTERED NUMBER.. 03575079 {England and Walè•) CHARITh REGISTERED NUMBER: 1077687 SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT IWOLVERHAMPTONI REPORT OF THE DIRECTORS AND FINANCIAL STATEMENTS FOR ThE YEAR ENDED 31ST MARCH 2024

SICKLE CELL AND TrIALASSAEMIA SUPPORT PR0￿CT IWOLVERHAMPTONI CONTENTS OF ThE FINANCIAL STATEMENTS FOR THE YEAR ENOED 31ST MARCH 2024 Pag• Report of the Dlrectors and Trusl•eS Statement of Trust￿. mwn¥ibili¢i Indtyendeniexmirterf¥ report Stat•ffl•nt of financial a¢ti¥ili 8alaDc• sho•t Not• to thè finanelal statèménts

SICKLE CELL AND THALASSAEPAA SUPPORT PROJECT (WOLVERHAMPTONI COMPANY INFORMATION FOR THE YEAR ENOEO 31ST MARCH 2024 DIRECTORSrniUSTEES: C R Crosdale D Mclntosh D A Mclnlos Dr D Katra L Ball L T Moowth Dcsmith A A Ezort￿n lappouiled 22 Septembef 20231 SECRETARY: S Hwjan REGISTERED OFFICE: Pay￿re Hou6 1$1 Floor G￿rge Streét Wolverhampton WV2 4DX REGISTEREO NUMBER: 03575079 IEn9land and Wales) REGISTERED CHARITY NUMBER: 1077687 INCEPENDENT EXAMINER: Neil HaThis FCA 8Sc (Honsl Cygnet Ac￿￿nting Lomited 37 RosseN Orive St8plelord Notbngham, NG9 7EG BANKeRS: Uoyds Bank Pk 37 Queen Square Wolvethamplon 1 1TL SOLICffORS: Wall James Chappell 1&23 Hagley Ro&1 SioU￿ridg9 DY8 1QW Page 1

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT IWOLVERHAMPTONI REPORT OF THE DIRECTORS AND TRUSTEES FORIHE YEAR ENOED 31ST MARCH 2024 The dire¢tofs, who •r• alsts trusiees of the charity. present the￿ report with th& flnan¢i•l slalemenls of Ihe company fof the Ye￿ erKted 31st Ma￿h 2024 The dIr￿lor3 have adopted the FV0Vi8￿n$ of the St¥temonl of Reeornmendod Pfactice {SORPI "A￿OUnt1r0 and Repo￿ng by Charilies" (FRS 1021 In preparir#J Ihe annual rerrt flnancial slatements PRINCIPAL ACTiwllES The pnnopal charitable adN4ts ol thè in the year under review were Ihose to rffO￿de rehef of povewty, sithness and distress. and enhartcemenl of lrfe. to those affeded by tho digvders Sickle Cell thsease and Thalassaemia. INing wthin the Wèst Midlands and surrounding a￿8$. Those so affectgd are predominanlty frryn Afr￿ll, Caribbean. Mediierranean and Asian communilies. In 2016 the charity had èxpandèd rta actNitw lo indud8 w¢yking wilh laNMlies %ilh complox and r￿ltsple needs, In tyderlo prornt•, S￿ngthen and iMprove Ihew life chances. DIRECTORS AND TRUSTEES The d￿t¢￿r5 aThJ Injstees dunng lh& yeac undei rewewwere". C R Crosda D MdntC6h D A Mclnlosh Dr O Kalra LB81 L T MgQfUth Dcsmth A A Ezomon {app)inled 22 September 20231 COMPANY STATUS The compafty Is lknlted ty guarantee and 1$ a regtslere(I ch8rity (Registered No 10776871. Thi$ ￿pOrt ha5 been prepa￿￿ In accordancè V4slh th¥ spKval prrniisions of Part 15 of Companiès A( 2006 relat￿9 to small companies. OBJECTS AND REVIEW OF THE COMPANY The report sets out ath"wI￿$ and athsev8menls of ihe charity for 2(f2312024 The organlsabon was fonn•d in Sept￿nber 1W) and founde¢J charity in I9￿. The objects of the charity allow the Irvstees lo devebp cthnprehensivety and consstentty hb9h quality 5eMces lor users, thelr carers, fatThls and profesS￿al$ who Interact wrth them. wlhin the w0￿￿rharnpton ant1 surrounding areas notabty Bla¢k Counlry and siaff¢fdshirè. The Tru$le¥s support a number of actNiti'es in purgjanl ol it$ objects These a￿ as Ic41ows To offer counsellin9 and screening lo Ihose irjdividuals aff•ciÈd by ce￿ or Th81ass88ffta To wovhle aou, swjport and guida￿ to affected ￿d￿ldualS. To incre85e awareness by d•vdoping educalijnal materials and promotion of rai¥ing awareness actiwlies_ To support both unNetsal and Voluntary screening pro9rammes To develop robusl conynunty development actryrtEs lo promole and support the affected communitses. To strengthen and supwt famifio5 rylh ￿MpleX and l￿al￿nging needs. The Truslees meet every thr¢¢ months lo miow overall perforrnance of ihe ¢harity ancl to gwe stsalegic guida1￿ The diredorsftrustees rewew. and consider, Ihe chanta￿e compan￿$ reserves In the context ol risks and funding In s¢M'n9 a ￿serveS policy the ¢Jireclors aim lo esta￿tsh reasonable but ntrt absolule otecbon againsl risks and lo balance this with the need lo deploy resour￿3 in pu(suil ol the ¢ornpany'3 tharilabb ciedNes Reseryes are Intended to.. 1) Prtsvide protection for fluctuats"on$ ir￿Orr￿ and expendilur 2} Ftsnd futur& investm￿1 needs and nonqecuNent wemis¥ co¥ts Opèratlonal Costs th the changes that have taken place during th& year il has ne¢essft4ted a of the ReSe￿e Poh'ry relat￿)n to OFeration8J belm1￿$. 11 is now pr￿oSed that the ￿serV¢S target shovkl al least cowf eh3hl monihs Page 2

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT IWOLVERHAMPTON) REPORT OF THE DIRECTORS AND TRUSTEES FOR THE YEAR ENDED 31ST MARCH 2024 ofopwalion indudlng redundanry cost. Thg new wopused figure is £225.CQO The ReseN•$ ¥1 •nd ofthe anrAal year 2024 %%tie £733,112 f2023.' £678.2611. Roni Costs SCTSP are CUTrenlty reshjing in 8 builjirrfj paying reduced d)8r9e. Thi5 nol be a long4asting a9￿ment and we cannot ￿ ceÉtsin in anyway shape or form that the management structure of the own¢rs of the L￿ik11n9 wll not charoe and thereby iwin lo charge rent that wll ¢2use malc¥ disrupii'¢)n to ihe opefational actNites of SCTSP. Wlh Ihis in mind It is our proposal that w8 begin tg build 8 reserve in Ihe accounts to cater lor this anomaty We are ￿rrentlY paying servu charge of about £9.750 perannum and 44t would expect that WÈ probabty should ba paying rènt somewhere in the regKin of É28,OCQ pe¥ 8nnum. It r& therefore proposed thal n Ihi¥ ys acwjnls we set a￿de £48,(th in d¢¥Jnate(l ￿seThe$. The majortty oflhe charitable company's fundin9 is from NHS contracls which nem)ally a￿ renewaNe on a 1- 2 year period. Add￿.0ftaI Ivnding is oblained from donalK)ns by supporters of the chaTty. ho￿Ver given Ihe economic d#mate, like many charities we have seen È reduction ift ihis Income, however we are still appfecialrve ol those who ¢ontinue lo collecl donations on behav of the tharty. We also ￿COgnISe thai those tho make such donation5 are to see our vs¢rs directty b•nefit (rom Iheir efforts and lo this end the Trustees have decKled thal Ihe majority of these fvndj wll go towards the Hardship Fund established ty the charity. Currentty a provision of £5.LMX) has beon sèl asidè and ¥vill be drawn down within eath yearfs èxpènditure dependlng on numbers of ind￿duat$ idenlified lo receive such support. The charity has invested $urplus funds Vith the objeclive to generaie ￿ndS throu9h capital 9rowlh. The fvnds are managed by Milsted Langdon and are mOn￿ored by the Finance Sub Commrttee with ￿QuIaT Teports to the Boafd A ¢auluus approach has been 18ken lo risk over lhe period lo r￿•¢t the volab.lity In the rnarket that can occur. ￿th lh sn(xease kn in¢oTr Ihe orgatNsalion VAII review rt¥ inveslrynt portfr)bo wth thi$ In M￿d. The Trustees regular￿ re¥ew lh& finances of tha chanty and #re pleased that a sallsfaciory ndapondent accountanl'$ ex8mnation has been athie¥ed. PUBLIC BENEFIT JI Ihe charity's actNilt8s aro 8lrned at supp(Klin9 loeal IrKINiduals affe(#ed by sid(le cell and th¥lassaemia and lamilies expenenung chanenges. In develop.ng aelivilS and deliverin9 seNices. the d￿8¢tO[S havè taken accounl of Ihe guidance published by ihe Charty Commww ￿ Publ￿ benefit. DEFINED BENEFIT PENSION SCHEME A full actuarial valuatKin was came(J oul as 0131 March 2022, thè ￿$￿￿$ of whth a￿ in notè 9 ofthe finantsal atatements Wrth respect kn this tiability Wotverhampton Cty Council has a9reeil to act as a guarantor towards Ihi$ liability. However, the re¢ent acbjarial valuatson, which shows a Curreni l￿bilty 01 £512,C(K), a¥ ilh pr8vKJus years. the TnJst8éswill ¢ontsnue lo be mlndful ol this labilty within ts overall resvè p)Iw. RISK MANAGEMENT The tnjsiees have considered ￿ Mai￿ nsks th8 chanly fè¢es. The tharrty's system of internal contrvls is esigned io provide reasonable bul not absolute assurance aga￿$¢ misslatemenl or los$ The truslees are satisfied Ihal the systems in plat mrt#3atè Ihv ¢harty's expwurè to Ihe major nsks. ON BEHALF OF THE BOARD: ortriu C R Crosdale- ￿.￿CtoriTrU51ee Date.. J>.¢o. The notes form part ofthe$e financtal statements Page 3

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT IWOLVERHAMPTONI STATEMENT OF TRUSTEES, RESPONSIBILITIES FOR THE YÉAR ENDED 31ST MARCH 2024 Thetrustees, a￿ Also IheiJirectNs of SI(￿￿ Cell ¥rKI Thalassaemrd Support Pr￿e¢l (Wo￿￿￿¥[￿10n) for Ihe purp05è of company law. art rèsrpj?&b￿ for preparing the TrLk%tees' Report an¢1 the financial stalements In accordance wilh aPplUb￿ law and Unrted Kingdom Accounting Standards (Unrted Kingdom Generalty ACC8p￿ AcLX)untsn9 Practs¢8). Corryjany Law requires the trustees lo prepare financial statéments each fina￿al yèar which gNe a true and lair view of the slate of affays of the chaiity and of ihe incoffdng resources and application of resourca$. irtduding the irlwme and expenditure, of the charitat4e company for that year In wepaiing these financial $tatenwnt$, the trustees ar& wulred to. - seleL suitsble aco)unth'ng polths an¢J Ihen apply them Lws15teNty.' - otserye U)e methods an¢J prinopb$ In Ihe Charfbes SORP. - make judgements and estimates Ihat a￿ reasonabk and prudentr. - state whet￿r applcable UK Accwnbn9 Stsndards have been folknved. 3Utyect lo any fflatsri•l (Iyrtu di5cbsed and explalned in the fin3n¢kal statements., and - mare th¢ financ1 statements on the png I￿&M basva unless It 15 inappropnate to presvme that the charty wll C￿ltinUe in operalion. Thetruste•s arè rèsponsibkg for kèeping adequate arLounting record5 Ihal disdose with reasonable accura al ary ts'me Ihe finanual positi)n ol the charity and enable them to ensure that the financial ststements cornpty with the Compan1es A¢1 20C They are also responsib￿ lor saleguafding the assets ol the charity and henr for tsking re8sonab￿ steps for the prewtk)n and deteGtion of fraud and other irregularities. The notes form part of Ihese financial slatements P80• 4

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT IWOLVERHAMPTONI INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31ST MARCH 2024 l ￿P)rt to ihe trust¢es on nyy wrinalion of th• finan¢ial $iatèm¢ftl$ ¢1 Sickl¢ C•ll And Th•l•$s••mia SupFOt Pro1￿1 (Wolvethary)lon} (the chadty) lor the yaar ended 31 March 2024. Respon$lb511tles and basls ol report A5 the Iwstees of the chanty land also rts directors ftjr Ihe puw85 ofcorroary law) you are resp(￿S￿)Ie for the preparation of ihe fwn(yal statements Sn accordan￿ wrth the requifements of the Compan￿$ Act 2006 Ilhe 2006 Acll. Havin9 sal￿fied rysÈff ihat Ihe financbal stalemenls of tre Charty are not requred to be authled under Part 16 of the 21J06 ki and elwJible for independent examinal￿n. I report in respecl of ry exarrmnabon of the ¢harty'$ financial $tatoments carried out und8r Ihe Charits"8s Acl Ilhè Ad). In earrying oul my ¢xamlrtaiw I ha¥e ltsltow¥d all the appliC8b￿ OtreciK)ns given ty the Chafty CoMmiss￿n under the Act. Independent examinÈ¢s •tat•m•nt I have completed rny examination I confim) that no matters Con￿ lo my attenb.on in Connel￿ wlh Ihe exam￿allOn giving cause to believe Ihal li any materkal respect- accounb.ng recofds were not k•pt n rtspèd ofthè ehanty as ￿¢'on 386 of 21J)6 Act,. 01 2. the financk?I stalen￿ntS do nol aeeord wth thou records, or 3 the financkal statements do not comply ￿th the a¢counbng ￿ul￿MentS ol 396 of the £t othar than any requ1reff￿nt Ihat thè aCC￿nts give a true and fair Vk8W whkh Is not a matter conS￿ered as part ofB Th independent exa{￿nation.. or 4 the finantial slatemenls have not been p￿Pared In aCCordar￿e with Ihe malhods and prin&p￿S of the Staitsment of R¢commended Praclw for accountin9 and reporting ty charities applicab￿ to charities preparing their accounts In awdanc& with So¢tson 1A "Small Entities" of Financjal Reporling Standard 102'Th¢ Financial Reporting Standard app￿ca￿e in Ihe UK RepublK of Irel￿d.. I ha¥¢ no concerns and have come acxoss no other matters in connects.on witA thè ax8m1n8t￿rt io wh¢h attenl*)n should be drawn in thL8 report in order lo enoble a pioper understand￿9 of Ihe financkal s1ateff￿nts to be reaethed. Neil H•rri$ FCA 8S¢ {Hon$j Cy9r￿1 Accountsng Limited 37 Rossell Drive Stsplelor Noltt'ngharn NG9 7EG OaleLI.. The notes form part ofthese financsal statements Page 5

SICKLE CELL ANO THALISSAEPAA SUPPORT PROJECT (WOLVERHAMPTONI STATEMENT OF FINANCIAL ACTIVITIES IINCLUDING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31ST ￿ft¢H 2024 Total Unrastricted Restricted Fund8 Funds Funds 2024 Totsl Funds 2023 Nots$ INCOME FROM.. Donatk)ns and other Income Investment Ineo Charitable activit.. Seryice level agreements from.. b￿erhaMPt0n Clhical Commi%￿OnI￿9 Giovp Dudley Clinical Commtssioning Gro Walsall Healthcare NHS Trust slaff￿dsh1ré CC- FSgJFIPIPPISapling 90,CQi 18.593 90,001 18,593 118.744 931 115.720 16.962 SJ.773 115.720 16,962 60,773 113.674 16,830 X).072 TOTAL INCOME EXPENDITURE ON: Ralsing funds 249 10.732 10.981 Charilable actNitTes 224 109 230 534 23S8 TOTAL EXPENDITURE 234.841 247 192 Net incom￿9 I lexpendilurel before gain or k)ss on investments 101,920 IS1.3661 50,834 116.721 un￿311$e1 gainllloss) on Investrnenls 4,317 4,317 15.688) Bala￿e$ broughl lothrd as at 1 Aprfl 2023 428 9L 249.355 678.261 Balartè$ ¢grried forward as 81 31 Marth Z024 678 261 The slatemenl of finana¥l ¥dNth'es includes 811 gains and k$se$ rgcowised wi th• year. All and expenditure derNe from ¢ontiniMng ¥rtivitses. The Stste￿nI of financaal aclNitle$ 8kn ts)mph￿ with the reqLllremants for an ￿¢1)mO aThJ 8XP8ndthr• account under Ihe Companles kl 20C6. The notes fomi part olth*¥e finandal stalements Pa9e 6

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT IWOLVERHAMPTONI NOTES TO THE STATEMENT OF FINANCIAL ACTMTIES FOR THE YEAR E140ED 31ST l•lARCH 2024 Totsl Unrestricled Restricted Fund¥ Funds Funds 2024 Totsl Fund$ 2023 RAISING FUNDS Wages ScKral SO￿rity Pensions Repairs & Mainten￿ce Telephone Sundry expenses Postage, pnnting a Sial￿nary Rent & 5etvice charge Insurance Oeprecialion- off￿e eqLF¥Jmenl Bank charges 157 10 24 7,687 473 1,162 137 7,986 577 1,135 97 sso 78 143 471 1,186 144 117 110 24 471 173 170 14 92 100 249 CHARITABLE ACTIVITIES Wagg5 Sw'al Security Pensions Siaff training Tcavellin9 Repairs & Mainten￿¢4 Social hardship donat￿ Sooal support Consullanq serv￿• d¢Vèh)pn￿t Sub3Gnpbons Telephone Sundry ¢xp¢ns¢s Postsge, printirKJ & ststimery Rent & 5•￿1￿ charge Insurance Deprecaation- olke equymenl SUp￿rt ￿$1$.. Board expenses Accountancy Profess￿￿31 fees 1.490 147.556 8,996 22.087 1.435 1,789 2,605 149.046 9.180 22.538 1.435 1,883 2.742 1.240 12,738 151.734 10,962 21,573 885 1,619 1,847 605 451 137 1240 12,736 1.500 2,1C 1,800 10,448 1,481 2,716 8,949 3,577 257 2.085 130 2.085 6,S09 2,220 2.199 8,949 3,291 6,379 2,109 2,089 8.770 3.225 81 110 179 117 1,473 123 1.SSO 1TrJ 2,160 77 42 The not¢s form part oflhese fmancial statements Pa9¢ 7

SICKLE CELL AND THALASSAEAIIA SUPPORT PROJECT (¥YOLVERHAMPTONI BALANCE SHEET 31ST MARCH 2024 2024 2023 Nolos Foxed a55ets Tar¥Jible assets 593 Curr•nt ass•ts Deblofs Inv•sim•nls Cash at bank aTrJ In hand 7,190 S2,924 1.020 48,607 71S.201 820,448 764,828 Credltors: Amounls falling due within one year 2.160 N•t ¢urrgnt 4¥8ets 817.608 762.868 Total assets less eurye Itabillllés 818.112 763.261 Cr•dltor8'. Amowls faI￿n0 du8 within one year N•t a#••ts 733112 678,261 Income funds UnresinJed fvnds: General funds Deslgnated lunds 4SS,143 348,SY)6 80.00 428,906 249.355 635,143 Re$l￿ted fvnds Total rneome fund¥ 733,112 678 281 The o)mpany h enIrt￿ to exemption from audrt under Secbon 477 of the Companies A¢i 20CIS lor Ihe year ded 31st March 2024. The direclors acknovAedg8 Iheir ￿spOnSibl11￿$ for corTh)tying with Ihe requirements of the Compan$ AL# 2006 wth respecl to accouniing records and the preparalion offinandal S&lemenl& The ffmbefs have not rwuired the company lo oblain an a￿111 tsf its financ￿1 statements for the year èndèd 31$t Marth 2024 In accordan¢e with Section 476 01 the Companwts A¢t 20C6. These finarthl stalen￿nIS have been prepa￿d h) a¢cwd•nce wfth Ihe provisions aPpI￿a￿ lo companies subject to the compani8s r8glmÉ. Thefinancigl statements wère approved bythe Board ofTrustee$on. wer¥ $gned on rts behalf by" L 8•11 D*rftorrrwslee C R Crosdale Company registratlon number 03575079 Page 8

81CKLE CELL AND THALASSAEMIA SUPPORT PROJECT IWOLVERHAMPTONI NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2024 Ae¢ountln9 poll¢l•8 Chartty Informatlon Sithe Cell and Thalassaemia Support Projecl (Wolverhamptoftl is a prNaie Company Iirryted by guaraniee M1￿[pOrated in Eng18nd and Wa￿S The re91ste￿d ofThce Is Paycafe House. 1st F￿￿. George Sifeel, W¢￿ve￿AmPIon, VVW2 4DX. The M￿berS of the ojmpany are the Injstees names on page 1. In Ihe evenl of Ihe charity being wound up. Ihe Iiabih'ty in res￿1 of ihe guarantee is I1￿11ed to £1 per member of the charty Aeeourttlng ¢on¥•ntlon The financ181 stalennts have been wepared und¢r th¢ hislorral cost convenlion and in accordance wth the prowsions of Section 1A-Small Entibès. of Financial Reporting Standard 102 'The Financial Repoth'ng Standard applicable in the UK and Republic ol Ireland", Ihe Charities Act. the Companies A¢ 20[￿ and Ihe Slalemenl ofRecomrnended Practice'."A¢¢ounb"ng and Reponing by Charit¢es- (FRS 1021 vath the exception of %counting lor Ihe deficit on the defined benefft pension scher￿, fw provision has been mad¢ 05 sel out b91ow and in note 9. The firbanoal $131ennls are prepared in stertlng, which Is the funclionol cutrvcy of thaTity. Monetary affrfjunts in these financial slalements are rounded to Ihè nèarèst £. Charftabl• funds ￿n￿$t￿le4 lunds are available lor use at the disc￿tKIn ol Ihe trustees #i fvtherartt0fth¢￿Ch¥rilabj8 obpcts.ves Dèslgrtaled lund$ corrrf)rlse unrestricted funds Ih8t have ten set aswje by the truslees for partlcular purposes. The akn and use of e3¢h desynated fvnd is set oul in Ihe notes lo Ihe financial slatemen Re$ln¢ltd funds are suty'ectlo specific COnd￿0￿S by donors aslo hcth Ihey mty be used. The purF4)￿s and usgs ofthe restrthd funds a￿ gel in Ihe notes lo the finandal Staten￿ls. Incorne lrtcomè 1$ re￿gnEed ¥then the chanty Is galty enti￿￿ to il after any F¢rf0M￿nCe condllons havg been mel, lh¢ ¥rTrJun15 ran be Ir￿asUred reliably, and it is Proba￿e that Inceme will be re￿Ned. Co$h donat￿nS are recognised on receijt. Other donations a￿ c¢¢ognis¢d once the thaiity ha5 bean nolified of thè don3lKJn. uftless performaTr￿ condthons requ1r8 def*Jral ol the arnounl Income tsx overable In rdation io dO￿tK}n$ re¢eNed under f)fft Aid or deeds of covenant Is recA)gnised al tho bme ofthe donafjon. Gifts In kind donaled for distribution are included 8t valu8tKJn and r•eognis4d ¥$ income when they are thslnbuled to the projecis. Gifts donal￿ for re$8b are included as income wh6n thèy are sokl. Donated faulrties are induded at Ihe value lo the d)ar¥ty wh?r¢ thi$ be quantif￿￿ and a third paty is bearing the cost No amoLEnts are includ6d in Ihe financial statements for s8rvic•s donat6d by volunteers. Expendlturo Expendrtur¢ 15 t90)gn￿ed orce there is a ￿gaI or constiuclve obligaton to Ironsfer econowic benefft to a third party, rt is probabl8 that a translèr of ÈtontsrTh¢ benefrts will be requwed In settknienl. 8nd Ihe ount of Ihe obligation can be measured r¢liably. E¥pendrture is C￿ss￿led ty actiwty. The ¢o$ts of eath aCti￿ty are up of the total of dlr•tt costs and shared costs. induding support costs inVo￿e￿ in undertaking each acliwity Direct costs allribulab to a single activily arg allg¢ated directty to that activrty. Shared costs wh￿h contnbute lo more Ihan one aclryty and support ¢c)sts whith are nol attribulab1e lo a single aclivity are appthoned belween those a¢iivrtie$ on a b?$1$ consistent with the usè of resources. Central staff Costs 8llocaled on the basls oltime spent, and depf¢tsalion charges Bre allocaled on Ihe portlon ol the assel's us¥. Page 9

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT ￿OLVERHAMPT0￿) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2024 Aecounting pollcles {eontinued) All expendIlu￿ is aco)unied for on an ¥¢¢xuals basis and has been Class￿ed under he¥rfings that ag9￿gate all costs reL3ted tg the ¢zleg0ry. costs cannot by directty altributed lo particu headings they have been allocated lo actiwtiès on a ba￿S consistent with use ol th& ￿SoUl¢es. Fu￿-T8131ng costs are those Nieurred In voluntary wntributions and do not include the costs of disseminaling informal)n in 5UPWrt ol the charilatJ8 acbviiies. Support costs are costs i￿Urred directy in support ol expenditurè on the objeds of the charity and indude prolect managennt carnied out at headquarter5. Management and acJmFnistratitsn costs arè Ihts5e incurred in vrtth the admin48tration ol the tharty and Corry)I￿n￿ wllh 4wn¥lrtuli¢>nal and statutcry requ1￿meThI¥. Tangiblè 15xed a$s•ts Tangible fcied assets are Inilwlty ffleasured al rAlSt and $ubsequenty moasurefl al cost or valuation, t ofdepreciatton and any inpalm￿l losses Depreciab"on is fecognised so as to wrile off Il cosl OT Yakt8tb of assets lesg Ihk r•s￿Ual values over their useful livo3 ￿ the foHowing bases. Plant and ma¢hinery Fixtures and fittings . 25% on cost - 15% & 25% on reA1uo'ng bakn Tho goin or bss artsing on the disp3sal of an asset is dèierrnned as the difference between the sale oceeds and the carying value of ihe asset, awhl 15 ￿Cognised in the slalemènt of finanaal actN Invèstments Investmenls am ¥lated at martet valu8 at the baLqnr sh8et date Thè SOFA Indudes the nel gain$ or knsses arising on ￿valUation thtoughwt the year. Ponsltsn8 The company operales a define(I ben8fft pensk)n schen whrch provkyes b￿effts basefl on final pensionabk pay. The scheme r& ¥d￿￿nIStered by Ihc West Midknds Pension Fund. Ènd the assels are held independently ol the finances ol the cornpany. Thè [￿st ￿￿01 full actuarral Wa￿atIon was carrd Out at 31 March 2022 The prqedgd valvabon defi¢il rn the scheme 8131 March 2022 was £512,000 the 8oard has considered Ihis s¢tualK)n and feels 1hal because ol the age of Ihe work lorce this def￿1t Can be eliminated ovei a period ol and currenlty a total wovision of £85.0￿ has been made lo date in these a¢eounts Restrieièd Fund8 Monies feceived as grants for particuL4r purposes are held 8$ separate Ivnds and a￿ ¢tgdrted to Ihe St#t8ment ol Financial Aclivils when costs of the particular r¢kvant projects are Leasos Rentals payable underoperaling leases, Including any lease incenlNe5 receNed. are charged toin¢ome on a straighl lu)e tsa5￿ over th¥ teffli ol Ihe ￿levant loase. P¥9¢ 10

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON} NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENOED 31ST MARCH 2024 STAFF COSTS 2024 2023 Wages and salaries Sodal securty costs Othgr pension costs 156.890 9,663 159.720 11.539 190.277 I93,￿7 The averag& nN)nthty numbèr olempKIyè8s durirrfJ the year was as follo￿. 2024 2023 Charitablo Workers There are no employees who re￿Ned lo181 emclunwnls olmore than £￿,0(￿). opgRATING PROFITIILOSSI 2024 2023 Oeprxi8tion- o*med 858ets 89 270 Oirectors, em0hJ￿nts other beneffls al¢ TANGIBLE FIXED ASSETS Plant and m8chinwy F[x￿re3 and fitting8 Totsl Cost At 1st Apru 2W23 Additions OIsp0581$ 23.824 13.391 37.215 At 31$1 Marth 2024 Dèprnelatlon Ai 1 st Apnl 2023 Chargè for year Eliminated on disposals 23.824 12,798 89 36.622 89 AI 31$1 March 2024 Nel book valuo Al 31sl March 2024 504 $04 At 31sl Mar¢h 2023 593 593 Page11

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT IWOLVERHAMPTON) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2024 DEBTORS.. AMOUNTS FALLING DUE WITHIN ONE YEAR 2024 2023 Pfepayments and accnjed ir￿r CURRENT ASSET INVESTMENTS 2024 2023 Archrtas Ma Pass￿& Modèts￿ s *£¢ 924 48.607 CREDITORS.. AMOUNTS FALLING DUE WITHIN ONE YEAR 2024 2023 Socyal 88oJrity and other lax Accruals and deferred incow 1840 CREDITORS.. AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR 2024 2023 Pfovtsion for dofmod pension stheme defKit Isee nole 91 PENSION SCHEME 2024 2023 Value of schemè assets and ￿'abIll￿5 Markel value of assets Pre$&nl value of schewe liabih'bes 820,IJQO 1332000 820.(M)O Penson 5theme defiol 512 000 The above is based M a v•lualion ¥131 March 2022. Piowsion of t85,0￿ ha$ been mmle tmrds Ihè above dèficit Page 12

SICKLE CELL AND THALASSAEMiA SUPPORT PROJECT IWOLVERHAMPTON) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2024 10. OPERATING LEASE COMMITMENTS Al the ￿pOrting end dale the charAy had outstandiig cowrnibnents forfithJre lease payments under nofve8n￿l1ab1e oper81iJyJ ￿3$e$. whlch fall as follows.. 2024 2023 thin one yeor 6ets¥een ￿ and fvo yars ANALYSIS OF ASSETS BETWEEN FUNDS Olher Not A￿etS Total Nel A55et9 Fixod Assets Unre$iricted Ful￿". General Funds Desynated Funds 455,143 .143 535,143 197.465 535.143 197.969 Rèstn"ct8d Funds 732.6CSg 733.112 11 RESTRICTED FUNDS Fund PufP)se of Fund Rea3on for Reslrlclion w0￿erharrp¢¢ft CCG sUp￿)rt the antenaial and newbom scleening Wjfverhaffolcn re5Klents progiamrr and proV￿e ¢ounsllirffj and support to Ihose affected Oudky CCG Support affected thildren WEth long term ndrtions to marTrag& their ¢ondilion Ihrough various wual and con¥nunty inteNent•)ns DUdF￿ rsidents on WaL%all Hèalthcare NHS Trusl Support the antenatal and newbom screentn9 Walsall reshjenls onty progr8mrne and provide counselling and support to Ihosè affecied Pag• 13

COMPANY REGISTERED NUMBER: 03575079 (England and Wales)

CHARITY REGISTERED NUMBER: 1077687

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

REPORT OF THE DIRECTORS AND

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31ST MARCH 2024

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2024

Page
Company Information 1
Report of the Directors and Trustees 2
Statement of Trustees' responsibilities 4
Independent examiner's report 5
Statement of financial activities 6
Balance sheet 8

Notes to the financial statements		 9

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

COMPANY INFORMATION FOR THE YEAR ENDED 31ST MARCH 2024

DIRECTORS/TRUSTEES: C R Crosdale D McIntosh D A McIntosh Dr D Kalra L Bell L T Mooruth D C Smith A A Ezomon (appointed 22 September 2023) SECRETARY: S Herian REGISTERED OFFICE: Paycare House 1st Floor George Street Wolverhampton WV2 4DX REGISTERED NUMBER: 03575079 (England and Wales) REGISTERED CHARITY NUMBER: 1077687 INDEPENDENT EXAMINER: Neil Harris FCA BSc (Hons) Cygnet Accounting Limited 37 Rossell Drive Stapleford Nottingham, NG9 7EG BANKERS: Lloyds Bank Plc 37 Queen Square Wolverhampton WV1 1TL SOLICITORS: Wall James Chappell 15-23 Hagley Road Stourbridge DY8 1QW

Page 1

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

REPORT OF THE DIRECTORS AND TRUSTEES FOR THE YEAR ENDED 31ST MARCH 2024

The directors, who are also trustees of the charity, present their report with the financial statements of the company for the year ended 31st March 2024. The directors have adopted the provisions of the Statement of Recommended Practice (SORP) “Accounting and Reporting by Charities” (FRS 102) in preparing the annual report and financial statements.

PRINCIPAL ACTIVITIES

The principal charitable activities of the company in the year under review were those to provide relief of poverty, sickness and distress, and enhancement of life, to those affected by the disorders Sickle Cell Disease and Thalassaemia, living within the West Midlands and surrounding areas. Those so affected are predominantly from African, Caribbean, Mediterranean and Asian communities. In 2016 the charity had expanded its activities to include working with families with complex and multiple needs, in order to promote, strengthen and improve their life chances.

DIRECTORS AND TRUSTEES

The directors and trustees during the year under review were:

C R Crosdale D McIntosh D A McIntosh Dr D Kalra L Bell L T Mooruth D C Smith A A Ezomon (appointed 22 September 2023)

COMPANY STATUS

The company is limited by guarantee and is a registered charity (Registered No 1077687). This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

OBJECTS AND REVIEW OF THE COMPANY

The report sets out activities and achievements of the charity for 2023/2024. The organisation was formed in September 1990 and founded as a charity in 1996. The objects of the charity allow the trustees to develop comprehensively and consistently high quality services for users, their carers, families and professionals who interact with them, within the Wolverhampton and surrounding areas notably Black Country and Staffordshire.

The Trustees support a number of activities in pursuant of its objects. These are as follows:

The Trustees meet every three months to review overall performance of the charity and to give strategic guidance. The directors/trustees review, and consider, the charitable company’s reserves in the context of risks and funding. In setting a reserves policy the directors aim to establish reasonable but not absolute protection against risks and to balance this with the need to deploy resources in pursuit of the company’s charitable objectives. Reserves are intended to:

Operational Costs

With the changes that have taken place during the year it has necessitated a review of the Reserve Policy in relation to operational activities. It is now proposed that the reserves target should at least cover eight months

Page 2

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

REPORT OF THE DIRECTORS AND TRUSTEES FOR THE YEAR ENDED 31ST MARCH 2024

of operation including redundancy cost. The new proposed figure is £225,000. The Reserves at the end of the financial year 2024 were £733,112 (2023: £678,261).

Rent Costs

SCTSP are currently residing in a building paying reduced service charge. This may not be a long-lasting agreement and we cannot be certain in anyway shape or form that the management structure of the owners of the building will not change and thereby begin to charge rent that will cause major disruption to the operational activities of SCTSP. With this in mind it is our proposal that we begin to build a reserve in the accounts to cater for this anomaly. We are currently paying service charge of about £9,750 per annum and we would expect that we probably should be paying rent somewhere in the region of £28,000 per annum. It is therefore proposed that in this year’s accounts we set aside £48,000 in designated reserves.

The majority of the charitable company’s funding is from NHS contracts which normally are renewable on a 1- 2 year period. Additional funding is obtained from donations by supporters of the charity, however given the difficult economic climate, like many charities we have seen a reduction in this income, however we are still appreciative of those who continue to collect donations on behalf of the charity. We also recognise that those who make such donations are keen to see our service users directly benefit from their efforts and to this end the Trustees have decided that the majority of these funds will go towards the Hardship Fund established by the charity. Currently a provision of £5,000 has been set aside and will be drawn down within each year’s expenditure depending on numbers of individuals identified to receive such support.

The charity has invested surplus funds with the objective to generate funds through capital growth. The funds are managed by Milsted Langdon and are monitored by the Finance Sub Committee with regular reports to the Board. A cautious approach has been taken to risk over the period to reflect the volatility in the market that can occur. With the increase in income the organisation will review its investment portfolio with this in mind.

The Trustees regularly review the finances of the charity and are pleased that a satisfactory independent accountant’s examination has been achieved.

PUBLIC BENEFIT

All the charity’s activities are aimed at supporting local individuals affected by sickle cell and thalassaemia and families experiencing challenges. In developing activities and delivering services, the directors have taken account of the guidance published by the Charity Commission on public benefit.

DEFINED BENEFIT PENSION SCHEME

A full actuarial valuation was carried out as at 31 March 2022, the results of which are shown in note 9 of the financial statements. With respect to this liability Wolverhampton City Council has agreed to act as a guarantor towards this liability. However, the recent actuarial valuation, which shows a current liability of £512,000, as with previous years, the Trustees will continue to be mindful of this liability within its overall reserve policy.

RISK MANAGEMENT

The trustees have considered the major risks the charity faces. The charity’s system of internal controls is designed to provide reasonable but not absolute assurance against misstatement or loss. The trustees are satisfied that the systems in place mitigate the charity’s exposure to the major risks.

ON BEHALF OF THE BOARD:

...................................................................... ………………………………………. L Bell - Director/Trustee C R Crosdale - Director/Trustee

Date:

The notes form part of these financial statements

Page 3

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

STATEMENT OF TRUSTEES' RESPONSIBILITIES FOR THE YEAR ENDED 31ST MARCH 2024

The trustees, who are also the directors of Sickle Cell and Thalassaemia Support Project (Wolverhampton) for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the trustees are required to:

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The notes form part of these financial statements

Page 4

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

INDEPENDENT EXAMINER’S REPORT FOR THE YEAR ENDED 31ST MARCH 2024

I report to the trustees on my examination of the financial statements of Sickle Cell And Thalassaemia Support Project (Wolverhampton) (the charity) for the year ended 31 March 2024.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charity’s financial statements carried out under the Charities Act (the Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under the Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

  1. accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or

  2. the financial statements do not accord with those records; or

  3. the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or

  4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with Section 1A “Small Entities” of Financial Reporting Standard 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland”.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

.................................................... Neil Harris FCA BSc (Hons)

Cygnet Accounting Limited 37 Rossell Drive Stapleford Nottingham NG9 7EG

Dated: ........................................

The notes form part of these financial statements

Page 5

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31ST MARCH 2024

Unrestricted
Funds

Notes
£

INCOME FROM:
Donations and other income
90,001
Investment income
18,593
Charitable activities:
Service level agreements from:
Wolverhampton Clinical Commissioning Group
-
Dudley Clinical Commissioning Group
-
Walsall Healthcare NHS Trust
-
Staffordshire CC – FSS/FIP/PP/Sapling
-
TOTAL INCOME
108,594
EXPENDITURE ON:
Raising funds
1
249
Charitable activities
2
6,425
TOTAL EXPENDITURE
6,674
Net incoming / (expenditure) before gain or
101,920
loss on investments
Unrealised gain/(loss) on investments
4,317
Balances brought forward as at 1 April 2023
428,906
Balances carried forward as at 31 March 2024
535,143
Restricted
Funds
£
-
-
115,720
16,962
50,773
-
183,455
10,732
224,109
234,841
(51,386)
-
249,355
197,969		 Total
Total
FundsFunds
2024
2023
£
£
90,001
118,744
18,593
931
115,720
113,674
16,962
16,630
50,773
50,072
-
63,862
292,049
363,913
10,981
11,331
230,534
235,861
241,515
247,192
50,534
116,721
4,317
(5,688)
678,261
567,228
733,112
678,261

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

The notes form part of these financial statements

Page 6

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

NOTES TO THE STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31ST MARCH 2024

Unrestricted
Funds

£

1
RAISING FUNDS
Wages
157
Social Security
10
Pensions
24
Repairs & maintenance
7
Telephone
7
Sundry expenses
6
Postage, printing & stationery
6
Rent & service charge
24
Insurance
3
Depreciation - office equipment
-
Bank charges
5
249
2
CHARITABLE ACTIVITIES
Wages
1,490

Social Security
184
Pensions
451
Staff training
-
Travelling
94
Repairs & maintenance
137
Social hardship donation
1,240
Social support
-
Consultancy service development
-
Subscriptions
2,085
Telephone
130
Sundry expenses
111
Postage, printing & stationery
110
Rent & service charge
179
Insurance
66
Depreciation - office equipment
4
Support costs:
Board expenses
6
Accountancy
77
Professional fees
61
6,425
Restricted
Funds
£
7,687
473
1,162
137
336
111
110
447
170
4
95
10,732
147,556

8,996
22,087
1,435
1,789
2,605
-
12,736
1,500
-
6,379
2,109
2,089
8,770
3,225
81
117
1,473
1,162

224,109
 Total
Total
FundsFunds
2024
2023
£
£
7,844
7,986
483
577
1,186
1,135
144
97
343
550
117
78
116
143
471
471
173
188
4
14
100
92
10,981
11,331
149,046
151,734
9,180
10,962
22,538
21,573
1,435
885
1,883
1,619
2,742
1,847
1,240
605
12,736
-
1,500
2,100
2,085
1,800
6,509
10,448
2,220
1,481
2,199
2,716
8,949
8,949
3,291
3,577
85
257
123
100
1,550
2,160
1,223
13,048
230,534
235,861

The notes form part of these financial statements

Page 7

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

BALANCE SHEET 31ST MARCH 2024

Notes
Fixed assets
Tangible assets
4
Current assets
Debtors
5
Investments
6
Cash at bank and in hand
Creditors:Amounts falling
due within one year
7
Net current assets
Total assets less current
liabilities
Creditors:Amounts falling
due within one year
8
Net assets
Income funds
Unrestricted funds:
General funds
Designated funds
Restricted funds
Total income funds		 2024
£
7,190
52,924
760,334
820,448
(2,840)		 £
504
817,608
818,112
85,000
733,112
455,143
80,000
535,143
197,969
733,112		 2023
£
1,020
48,607
715,201
764,828
(2,160)		 £
593
762,668
763,261
85,000
678,261
348,906
80,000
428,906
249,355
678,261

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st March 2024.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st March 2024 in accordance with Section 476 of the Companies Act 2006.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees on …………………………………………. and were signed on its behalf by:

.................................................... ………………………………………. L Bell C R Crosdale Director/Trustee Director/Trustee

Company registration number 03575079

Page 8

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2024

1. Accounting policies

Charity information

Sickle Cell and Thalassaemia Support Project (Wolverhampton) is a private company limited by guarantee incorporated in England and Wales. The registered office is Paycare House, 1st Floor, George Street, Wolverhampton, WV2 4DX. The members of the company are the trustees names on page 1. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity.

Accounting convention

The financial statements have been prepared under the historical cost convention and in accordance with the provisions of Section 1A “Small Entities” of Financial Reporting Standard 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland”, the Charities Act, the Companies Act 2006 and the Statement of Recommended Practice: “Accounting and Reporting by Charities” (FRS 102) with the exception of accounting for the deficit on the defined benefit pension scheme, for which provision has been made as set out below and in note 9.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Designated funds comprise unrestricted funds that have been set aside by the trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Gifts in kind donated for distribution are included at valuation and recognised as income when they are distributed to the projects. Gifts donated for resale are included as income when they are sold. Donated facilities are included at the value to the charity where this can be quantified and a third party is bearing the cost. No amounts are included in the financial statements for services donated by volunteers.

Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset’s use.

Page 9

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2024

1. Accounting policies (continued)

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Where costs cannot by directly attributed to particular headings they have been allocated to activities on a basis consistent with use of the resources.

Fund-raising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are costs incurred directly in support of expenditure on the objects of the charity and include project management carried out at headquarters. Management and administration costs are those incurred in connection with the administration of the charity and compliance with constitutional and statutory requirements.

Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and machinery - 25% on cost Fixtures and fittings - 15% & 25% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

Investments

Investments are stated at market value at the balance sheet date. The SOFA includes the net gains or losses arising on revaluation throughout the year.

Pensions

The company operates a defined benefit pension scheme which provides benefits based on final pensionable pay. The scheme is administered by the West Midlands Pension Fund, and the assets are held independently of the finances of the company. The most recent full actuarial valuation was carried out at 31 March 2022. The projected valuation deficit in the scheme at 31 March 2022 was £512,000 the Board has considered this situation and feels that because of the age of the work force this deficit can be eliminated over a period of time and currently a total provision of £85,000 has been made to date in these accounts.

Restricted Funds

Monies received as grants for particular purposes are held as separate funds and are credited to the Statement of Financial Activities when costs of the particular relevant projects are incurred.

Leases

Rentals payable under operating leases, including any lease incentives received, are charged to income on a straight line basis over the term of the relevant lease.

Page 10

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2024

2. STAFF COSTS

2024
£
Wages and salaries
156,890

Social security costs
9,663
Other pension costs
23,724
190,277

The average monthly number of employees during the year was as follows:
2024
Charitable Workers
5
There are no employees who received total emoluments of more than £60,000.		 2023
£
159,720
11,539
22,708
193,967
2023
5

3. OPERATING PROFIT/(LOSS)

4.

2024
£
Depreciation - owned assets
89
Directors' emoluments and other benefits etc
-
TANGIBLE FIXED ASSETS
Plant and Fixtures and
machinery fittings
£
£

Cost
At 1st April 2023
23,824
13,391
Additions
-
-
Disposals
-
-
At 31st March 2024
23,824
13,391
Depreciation
At 1st April 2023
23,824
12,798
Charge for year
-
89
Eliminated on disposals
-
-
At 31st March 2024
23,824
12,887
Net book value
At 31st March 2024
-
504
At 31st March 2023
-
593		 2023
£
270
-
Total
£
37,215
-
-
37,215
36,622
89
-
36,711
504
593

Page 11

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2024

5.
DEBTORS: AMOUNTS FALLING
DUE WITHIN ONE YEAR
Prepayments and accrued income
6.
CURRENT ASSET INVESTMENTS
Architas MA Passive Moderate S Acc
7.
CREDITORS: AMOUNTS FALLING
DUE WITHIN ONE YEAR
Social security and other tax
Accruals and deferred income
8.
CREDITORS: AMOUNTS FALLING
DUE AFTER MORE THAN ONE YEAR
Provision for defined pension scheme deficit (see note 9)
9.
PENSION SCHEME
Value of scheme assets and liabilities
Market value of assets
Present value of scheme liabilities
Pension scheme deficit		 2024
2023
£
£
7,190
1,020
2024
2023
£
£
52,924
48,607
2024
2023
£
£
-
-
2,840
2,160
2,840
2,160
2024
2023
£
£
85,000
85,000
2024
2023
£
£
820,000
820,000
(1,332,000
(1,332,000)
(512,000)
(512,000)

The above is based on a valuation at 31 March 2022. Provision of £85,000 has been made towards the above deficit.

Page 12

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2024

10. OPERATING LEASE COMMITMENTS

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

Within one year
Between two and five years		 2024
2023
£
£
-
-
-
-
-
-

11. ANALYSIS OF NET ASSETS BETWEEN FUNDS




Unrestricted Funds:
General Funds
Designated Funds
Restricted Funds
Fixed

Assets

£

-
-
-
504
504		 Other

Net

Assets

£
455,143

80,000
535,143

197,465

732,608
 Total
Net
Assets
£
455,143
80,000
535,143
197,969
733,112

12. RESTRICTED FUNDS

Fund Purpose of Fund

Reason for Restriction

Wolverhampton CCG Support the antenatal and newborn screening programme and provide counselling and support to those affected

Wolverhampton residents only

Dudley CCG Support affected children with long term conditions to manage their condition through various social and community interventions

Dudley residents only

Walsall Healthcare NHS Trust Support the antenatal and newborn screening Walsall residents only programme and provide counselling and support to those affected

Page 13